Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Toxicity to reproduction

Currently viewing:

Administrative data

screening for reproductive / developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Study period:
Study initiated October 2019, Dose Range Finding (DRF) Study October 2019, Necropsy November 2019.
1 (reliable without restriction)

Data source

Reference Type:
study report
Report date:

Materials and methods

Principles of method if other than guideline:
DRF study for “Combined 28-day repeated dose toxicity study with the reproduction/developmental toxicity screening of FeF cetyl trimethyl ammonium bromide (CTAB) USP/NF by oral gavage in rats” to follow OECD Guideline 422. Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test, July 2016 and EPA Health Effects Test Guideline OPPTS 870.3650: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test, July 2000
GLP compliance:
DRF study perfomed according to GLP,. Reported in Appendix 6, Appendix 7 and Appendix 8 of the report on main study 20212915

Test material

Constituent 1
Chemical structure
Reference substance name:
Cetrimonium bromide
EC Number:
EC Name:
Cetrimonium bromide
Cas Number:
Molecular formula:
cetrimonium bromide
Test material form:
Specific details on test material used for the study:
White powder
Batch (Lot) Number: GX0B433
Expiry date: 31 December 2022
Purity: 100% according to certificate of analysis

Test animals


Administration / exposure

Route of administration:
oral: gavage
Details on exposure:
Dose levels: 0, 50, 100, 200, 300 mg/kg bw/day
Duration of treatment / exposure:
14 days
Frequency of treatment:
No. of animals per sex per dose:
3 female rats/ group

Results and discussion

Results: P0 (first parental generation)

General toxicity (P0)

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
All rats treated at 100, 200 and 300 mg/kg/day were sacrificed moribund at Day 5, 4 and 3 respectively. Cause of moribundity were considered test item-related forestomach lesions in all rats in the form of the macroscopic finding irregular surface with the microscopic correlate ulceration/erosion of the forestomach up to marked degree. This was accompanied by (sub) mucosal edema (up to moderate) and lymphogranulocytic inflammation (up to marked) and/or squamous cell hyperplasia (minimal).
Furthermore, findings in the glandular stomach were noted which consisted of a focal ulcer at 300 mg/kg/day (minimal) and from 200 mg/kg/day onward a slightly increased incidence of granulocytic infiltrate (minimal). Although these findings can be seen as spontaneous background findings, a relationship with treatment with the test item for these latter two findings cannot be excluded.
Minor findings were noted for the intestines which included a minor increase in incidence and/or severity of inflammatory cell infiltrate (up to slight) at 200 and/or 300 mg/kg/day and epithelial necrosis in the duodenum of one rat treated at 300 mg/kg/day (minimal). A test item-relationship cannot be excluded.
There was no microscopic correlate for the macroscopic finding gelatinous contents (considered test item-related) noted in the stomach of all 300 mg/kg/day treated rats and in the intestinal tract of all rats treated at 100, 200 and 300 mg/kg/day.
There were no test item-related morphologic alterations in rats treated at 50 mg/kg/day for 14 consecutive days.
Dermal irritation (if dermal study):
not specified
mortality observed, treatment-related
Body weight and weight changes:
not specified
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
not specified
Clinical biochemistry findings:
not specified
Urinalysis findings:
not specified
Behaviour (functional findings):
not specified
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
not specified
Histopathological findings: non-neoplastic:
not specified
Histopathological findings: neoplastic:
not specified
Other effects:
not specified

Effect levels (P0)

open allclose all
Key result
Dose descriptor:
Effect level:
ca. 50 mg/kg bw/day (actual dose received)
Based on:
test mat.
Basis for effect level:
gross pathology
Key result
Dose descriptor:
Effect level:
ca. 100 mg/kg bw/day (actual dose received)
Based on:
test mat.
Basis for effect level:
gross pathology

Results: F1 generation

Effect levels (F1)

Remarks on result:
not determinable because of methodological limitations

Overall reproductive toxicity

Reproductive effects observed:
not specified

Applicant's summary and conclusion

Adverse test item-related morphologic alterations following the administration of FeF Cetyl Trimethyl Ammonium Bromide (CTAB) USP/NF were noted at 100, 200 and 300 mg/kg/day in the form of an early onset of moribundity related with marked forestomach ulceration/erosion and concomitant findings, as edema, inflammation and squamous cell hyperplasia.

Treatment for 14 days at 50 mg/kg/day was well tolerated.
Due to the observed steep dose-reponse relationship for forestomach ulceration/erosion and because of longer exposure period in the main study, the maximum dose in the main study should be no higher than 50 mg/kg bw/day.